NCT03279263View on ClinicalTrials.gov

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

PHASE2UnknownINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MLR-1023

MLR-1023 Tablets

OTHER

Placebo

Matching Placebo Tablets

Trial Locations (1)

90057

National Research Institute, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Bukwang Pharmaceutical, Co., Ltd.

INDUSTRY

lead

Melior Pharmaceuticals

OTHER

NCT03279263 - An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy | Biotech Hunter | Biotech Hunter